NVNO enVVeno Medical

Press releases

From Benzinga Pro
enVVeno Medical to Present at the Virtual Investor Roundtable Event
16 Nov 21
Biotech, News, Press Releases
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ETIRVINE, CA / ACCESSWIRE /
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11 Nov 21
Biotech, Earnings, Press Releases
- Quarter marked by corporate rebranding and strategic prioritization of development programs- Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
4 Nov 21
News, Press Releases
- Access the event and schedule of presenting companies at -- Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies -PITTSTOWN, NJ /
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
22 Oct 21
Biotech, News, Press Releases
75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI)Severe CVI Impacts Approximately 2.4 million U.S. Patients with
enVVeno Medical Corporation Successfully Completes Rebranding
1 Oct 21
Biotech, News, Press Releases
Company Now Trading Under Ticker Symbol "NVNO"IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
24 Sep 21
Biotech, News, Press Releases
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe LaboratoriesIRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories,
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
21 Sep 21
Biotech, News, Press Releases
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -- Development strategy to focus on venous disease and advancement of the VenoValve® --
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
15 Sep 21
Biotech, News, Press Releases
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
7 Sep 21
Biotech, News, Press Releases
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive